Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine symbols : Jnj save search
Vaccine Market Insights Revealed in New 2024 Global Industry Report
Published: 2024-03-22 (Crawled : 16:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
report vaccine global market
Global Respiratory Disease Vaccine Market Set for Growth, Fueled by Aging Populations and Vaccine Mandates - Trends, Opportunities, and Forecasts, 2018-2028F
Published: 2024-01-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 2.63%
H: 0.8%
C: 0.75%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 1.8%
H: 0.14%
C: -0.89%
disease vaccine respiratory global set market
FDA Panel Sets Possible Precedent; Novavax Wins Approval for Updated COVID-19 Vaccine
Published: 2023-10-05 (Crawled : 15:30) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.4%
H: 2.05%
C: 1.82%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
covid-19 fda vaccine approval
Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative
Published: 2023-10-03 (Crawled : 17:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.26%
H: 0.53%
C: 0.43%
covid-19 initiative vaccine nextgen
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
Published: 2023-10-03 (Crawled : 06:00) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.26%
H: 0.53%
C: 0.43%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
vaccine potential agreement sanofi
Empowering Healthcare: Global Vaccine Management System Market to Reach $441.17 million by 2028
Published: 2023-08-30 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -2.26%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.25%
H: 0.47%
C: -1.08%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.54%
H: 0.27%
C: -0.59%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 0.46%
H: 0.17%
C: -0.86%
management vaccine reach global system market
J&J Cuts R&D at Netherlands Infectious Disease, Vaccine Unit
Published: 2023-08-24 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
netherlands vaccine
Bavarian Nordic Drops Out of RSV Vaccine Race with Phase III Flop
Published: 2023-07-24 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.77%
H: 1.35%
C: -0.24%
vaccine rsv
J&J Drops Out of RSV Race, Cuts Late-Stage Vaccine Candidate
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.18%
H: 0.14%
C: -0.1%
candidate vaccine rsv
Global Vaccines Market Research Report 2022-2027: A $200+ Billion Industry - Forecasts, Company Market Share and Expert Market Estimates for Vaccine Categories
Published: 2023-02-08 (Crawled : 16:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: -0.09%
H: 1.26%
C: 0.99%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.06%
H: 0.77%
C: 0.19%
EBS | News | $2.18 -4.8% 3.21% 800K
|
Health Technology
|
| O: -0.78%
H: 0.79%
C: -5.29%
SNGX | $0.383 -4.25% -3.9% 480K
|
Health Technology
|
| O: -0.07%
H: 4.9%
C: 2.27%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
NVAX | $4.15 -0.96% -0.96% 2M
|
Health Technology
|
| O: 0.0%
H: 1.74%
C: -4.13%
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: -1.61%
H: 2.73%
C: -8.47%
BNTX | News | $88.09 -0.45% -0.35% 230K
|
Health Technology
|
| O: -1.35%
H: 1.53%
C: 0.68%
research global report vaccine market
Aeolian Biotech Corp. Formed to Create an Improved Pneumococcal Vaccine with Experienced Vaccine Development Leadership Team
Published: 2023-01-30 (Crawled : 00:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: 0.0%
H: 0.79%
C: -0.55%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.18%
H: 0.36%
C: -3.53%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
DVAX | $11.42 -2.89% -2.98% 1.5M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: -2.81%
biotech vaccine pneumococcal
J&J Shuts Down Second HIV Vaccine Trial in as Many Years
Published: 2023-01-19 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.43%
H: 1.33%
C: 0.3%
vaccine hiv trial
Worldwide Vaccines Industry to 2029 - Combination Vaccines Remain a Significant Growth Contributor to Vaccine Spaces
Published: 2023-01-06 (Crawled : 21:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
| Email alert
Add to watchlist
MRNA | News S | $108.85 0.89% 0.85% 3M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
vaccine growth
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
Published: 2022-12-23 (Crawled : 08:00) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.2%
H: 0.48%
C: 0.46%
defense vaccine virus agreement
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults
Published: 2022-12-22 (Crawled : 13:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.51%
H: 0.42%
C: 0.15%
candidate global vaccine rsv trial
Travel Vaccine Global Market Report 2022: Growth Potential in Emerging Economies Presents Lucrative Opportunities
Published: 2022-12-06 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.74%
H: 8.46%
C: 8.46%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.64%
H: 0.04%
C: -2.12%
ABT | News | $106.89 -0.65% 0.07% 4.2M
|
Health Technology
|
| O: -0.4%
H: 0.4%
C: -1.08%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.48%
H: 1.59%
C: 0.69%
global report vaccine travel potential growth market
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
Published: 2022-11-30 (Crawled : 12:20) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.16%
H: 0.93%
C: 0.92%
ACIU | $2.37 -0.42% -2.15% 320K
|
Health Technology
|
| O: 9.16%
H: 0.0%
C: -10.84%
aci-35 disease aci-35.030 alzheimer’s vaccine
Nuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in China
Published: 2022-11-14 (Crawled : 03:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: 0.0%
clearance pharma vaccine application respiratory virus china
Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial
Published: 2022-11-01 (Crawled : 17:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
covid vaccine trial positive results
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
Published: 2022-10-17 (Crawled : 07:00) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: 0.0%
covid-19 candidate antibody vaccine six trial response phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.